DE60227507D1 - Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit - Google Patents
Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheitInfo
- Publication number
- DE60227507D1 DE60227507D1 DE60227507T DE60227507T DE60227507D1 DE 60227507 D1 DE60227507 D1 DE 60227507D1 DE 60227507 T DE60227507 T DE 60227507T DE 60227507 T DE60227507 T DE 60227507T DE 60227507 D1 DE60227507 D1 DE 60227507D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- dosed
- low
- alzheimer disease
- lhrh antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 abstract 1
- 229960003230 cetrorelix Drugs 0.000 abstract 1
- 108700008462 cetrorelix Proteins 0.000 abstract 1
- 239000002474 gonadorelin antagonist Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60227507D1 true DE60227507D1 (de) | 2008-08-21 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60227507T Expired - Fee Related DE60227507D1 (de) | 2001-04-30 | 2002-04-27 | Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (enExample) |
| EP (1) | EP1392348B1 (enExample) |
| JP (1) | JP2004529207A (enExample) |
| KR (1) | KR20040000446A (enExample) |
| CN (1) | CN1317030C (enExample) |
| AT (1) | ATE400287T1 (enExample) |
| AU (1) | AU2002310788B2 (enExample) |
| BG (1) | BG108339A (enExample) |
| BR (1) | BR0209290A (enExample) |
| CA (1) | CA2444876A1 (enExample) |
| CZ (1) | CZ20033167A3 (enExample) |
| DE (1) | DE60227507D1 (enExample) |
| DK (1) | DK1392348T3 (enExample) |
| ES (1) | ES2307760T3 (enExample) |
| HU (1) | HUP0400067A2 (enExample) |
| IL (1) | IL156777A0 (enExample) |
| MX (1) | MXPA03008666A (enExample) |
| NO (1) | NO20034322L (enExample) |
| NZ (1) | NZ544417A (enExample) |
| PL (1) | PL362319A1 (enExample) |
| PT (1) | PT1392348E (enExample) |
| RU (1) | RU2319501C2 (enExample) |
| SI (1) | SI1392348T1 (enExample) |
| SK (1) | SK14512003A3 (enExample) |
| UA (1) | UA80679C2 (enExample) |
| WO (1) | WO2002102401A1 (enExample) |
| ZA (1) | ZA200305326B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| PT1300398E (pt) | 2000-07-05 | 2006-07-31 | Astellas Pharma Inc | Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| MXPA06014131A (es) * | 2004-06-04 | 2007-03-07 | Astellas Pharma Inc | Derivado de propano-1,3-diona o su sal. |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| EP2425846A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| SI1864976T1 (sl) * | 2005-03-31 | 2012-12-31 | Astellas Pharma Inc. | Propan-1,3-dionski derivat ali njegova sol |
| WO2008046919A2 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| AU2008303928A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection |
| AU2008306264A1 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| EP2095818A1 (en) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| EP2307040B1 (en) * | 2008-05-29 | 2015-09-09 | Isr Immune System Regulation Ab | Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| CA2254769A1 (en) | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| EP1185530A1 (en) | 1999-05-14 | 2002-03-13 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| MXPA02003614A (es) | 1999-10-15 | 2002-10-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos.. |
| US20030134863A1 (en) | 2000-04-13 | 2003-07-17 | Shuichi Furuya | Preventives/remedies for alzheimer's disease |
| PT1300398E (pt) * | 2000-07-05 | 2006-07-31 | Astellas Pharma Inc | Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta |
-
2002
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322L/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20034322D0 (no) | 2003-09-26 |
| EP1392348B1 (en) | 2008-07-09 |
| ZA200305326B (en) | 2003-07-30 |
| JP2004529207A (ja) | 2004-09-24 |
| SI1392348T1 (sl) | 2008-12-31 |
| RU2003134949A (ru) | 2005-02-10 |
| BR0209290A (pt) | 2004-07-13 |
| IL156777A0 (en) | 2004-02-08 |
| US7288517B2 (en) | 2007-10-30 |
| RU2319501C2 (ru) | 2008-03-20 |
| NZ544417A (en) | 2008-03-28 |
| CN1575185A (zh) | 2005-02-02 |
| SK14512003A3 (sk) | 2004-08-03 |
| HK1072000A1 (en) | 2005-08-12 |
| PL362319A1 (en) | 2004-10-18 |
| CZ20033167A3 (cs) | 2004-08-18 |
| US20020177556A1 (en) | 2002-11-28 |
| DK1392348T3 (da) | 2008-09-29 |
| BG108339A (bg) | 2004-11-30 |
| PT1392348E (pt) | 2008-09-09 |
| HUP0400067A2 (hu) | 2004-04-28 |
| NO20034322L (no) | 2003-09-26 |
| MXPA03008666A (es) | 2004-10-15 |
| AU2002310788B2 (en) | 2007-04-05 |
| KR20040000446A (ko) | 2004-01-03 |
| CN1317030C (zh) | 2007-05-23 |
| WO2002102401A1 (en) | 2002-12-27 |
| ATE400287T1 (de) | 2008-07-15 |
| CA2444876A1 (en) | 2002-12-27 |
| EP1392348A1 (en) | 2004-03-03 |
| ES2307760T3 (es) | 2008-12-01 |
| UA80679C2 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE400287T1 (de) | Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit | |
| EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| WO2002002518A3 (en) | Compounds to treat alzheimer's disease | |
| WO2002002520A3 (en) | Compounds to treat alzheimer's disease | |
| AT500379B8 (de) | Tau-proteine | |
| DE60221665D1 (de) | Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten | |
| NO2016007I1 (no) | Susoktokog | |
| EA200602015A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
| ATE414519T1 (de) | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
| ATE438405T1 (de) | Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes | |
| ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| DE60227283D1 (de) | Substituierte diketopiperazine als oxytocin-antagonisten | |
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| BR9801132A (pt) | N-heterociclos fundidos, substituìdos com benzilóxi, processo para a sua preparação e seu uso como antagonistas de receptor de bradiquinina. | |
| DK1007040T3 (da) | Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom | |
| DE59900222D1 (de) | Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| DE60117541D1 (de) | Candesartan zur Behandlung von Migräne | |
| MXPA03008406A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina. | |
| ATE449607T1 (de) | Arsentherapie zur behandlung von autoimmunerkrankungen | |
| DE60122764D1 (de) | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |